Bio-Thera Inks EUR 136m Deal with STADA for BAT1806 Commercialization
CompanyDeals

Bio-Thera Inks EUR 136m Deal with STADA for BAT1806 Commercialization

3D Medicines and CATUG Biotech Forge Strategic Alliance in mRNA-LNP Innovation
CompanyDeals

3D Medicines and CATUG Biotech Forge Strategic Alliance in mRNA-LNP Innovation

Bio-Thera Adjusts BAT3306 Clinical Study to Meet Regulatory Standards
CompanyDrug

Bio-Thera Adjusts BAT3306 Clinical Study to Meet Regulatory Standards

Novartis' Atrasentan Approved by China NMPA for IgAN Treatment
CompanyDrug

Novartis’ Atrasentan Approved in China for IgAN Proteinuria Reduction

Suzhou Zelgen's ZG005 and Gecacitinib Win NMPA Approval for Advanced Solid Tumors
CompanyDrug

Suzhou Zelgen’s ZG005 and Gecacitinib Win NMPA Approval for Advanced Solid Tumors

Minova's MI078 Shows Promising Results in Postpartum Depression Trial
Others

Minova’s MI078 Shows Promising Results in Postpartum Depression Trial

Abbisko's ABSK043 Gains IND Approval for KRAS G12C NSCLC in Partnership with Allist
CompanyDeals

Abbisko’s ABSK043 Gains IND Approval for KRAS G12C NSCLC in Partnership with Allist

Sino Biopharma's Zongertinib Receives Second Breakthrough Designation for NSCLC
CompanyDrug

Sino Biopharma’s Zongertinib Receives Second Breakthrough Designation for NSCLC

Haohai Biotech Terminates OK Lens Distribution Deal with Brighten Optix Amid Carl Zeiss Acquisition
CompanyDeals

Haohai Biotech Terminates OK Lens Distribution Deal with Brighten Optix Amid Carl Zeiss Acquisition

Nanjing Zenshine Pharma Partners with Cigalah Medpharm to Advance Sebaloxavir Marboxil in MENA
CompanyDeals

Nanjing Zenshine Pharma Partners with Cigalah Medpharm to Advance Sebaloxavir Marboxil in MENA

China Releases Draft Guidelines for Single-Arm Oncology Trials to Support Drug Approvals
Policy / Regulatory

China Releases Draft Guidelines for Single-Arm Oncology Trials to Support Drug Approvals

Ascentage Pharma Reports H1 2025 Financial Results, Shows Strong Growth in Olverembatinib Sales
Company

Ascentage Pharma Reports H1 2025 Financial Results, Shows Strong Growth in Olverembatinib Sales